Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection

Burge, Kathryn; Gunasekaran, Aarthi; Eckert, Jeffrey; Chaaban, Hala

doi:10.3390/ijms20081912

Cited by 118 publications

(106 citation statements)

References 352 publications

(508 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curcumin, with the advantages of low‐cost, reliable sources and low side effects, is holding considerable attention for UC treatment. Its significant NF‐κB inhibition, expressed by regulating NF‐κB/IκB pathway and down‐regulating expression of pro‐inflammatory cytokines, was thought to be the key mechanism for the anti‐inflammatory …”

Section: Discussionmentioning

confidence: 99%

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

Zheng

Wang

Chen

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: Aminosalicylic acids are recognized to be the first-line treatment options for ulcerative colitis. Currently, the effectiveness of curcumin as an adjuvant treatment in ulcerative colitis has been investigated, which was still controversial. This study aimed to systematically review and meta-analyze the efficacy and safety of curcumin as an adjuvant treatment in ulcerative colitis. Methods: The PubMed, EMBASE, and Cochrane Library databases were searched from original to July 2019, and relevant randomized controlled clinical trials were enrolled and analyzed. The primary outcomes were clinical and endoscopic remission; meanwhile, the secondary outcomes were clinical and endoscopic improvement. Subgroup analyses of doses, delivery way, form, and intervention time of curcumin were also conducted. Results: Six randomized controlled clinical trials with a total of 349 patients were included. Eligible trials suggested that adjuvant curcumin treatment in ulcerative colitis was effective in inducing clinical remission (odds ratio [OR] = 5.18, 95% confidence interval [CI]: 1.84-14.56, P = 0.002), endoscopic remission (OR = 5.69, 95% CI: 1.28-25.27, P = 0.02), and endoscopic improvement (OR = 17.05, 95% CI: 1.30-233.00, P = 0.03), but not in clinical improvement (OR = 4.79, 95% CI: 1.02-22.43, P = 0.05). We can see the potential advantages in large dosage, topical enema, special drug form, and longer duration from the enrolled studies. There were no severe side effects reported. Conclusions: Curcumin, as an adjuvant treatment of mesalamine, was proved to be effective and safe in ulcerative colitis. Better efficacy can be achieved with suitable dose, delivery way, formation, and intervention time, which needs further study to verify. Figure 1 The results of the inverted funnel plot analysis of the (a) clinical remission, (b) endoscopic remission, (c) clinical improvement, and (d) endoscopic improvement. [Color figure can be viewed at wileyonlinelibrary.com] T Zheng et al. Effect of curcumin in ulcerative colitis

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

Zheng

Wang

Chen

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…While the sequence of events in NEC etiology remains unclear, the disease is likely initiated by an excessive stimulation of toll-like receptor 4 (TLR4) by Gram-negative bacteria [31] in the ileum of the premature infant. Activation of this receptor [32][33][34][35][36][37][38] leads to extensive inflammation, denoted by apoptosis of enterocytes along the luminal border, impaired replacement of these enterocytes, increased release of proinflammatory cytokines and chemokines, and, in total, breakdown of the intestinal barrier [39][40][41]. This impaired intestinal barrier allows for greater bacterial translocation [42], leading to increased inflammation via direct contact of pathogenic bacterial antigens with the mucosal immune system [43].…”

Section: Pathogenesis Of Necrotizing Enterocolitismentioning

confidence: 99%

The Role of Glycosaminoglycans in Protection from Neonatal Necrotizing Enterocolitis: A Narrative Review

et al. 2020

Self Cite

View full text Add to dashboard Cite

Necrotizing enterocolitis, a potentially fatal intestinal inflammatory disorder affecting primarily premature infants, is a significant cause of morbidity and mortality in neonates. While the etiology of the disease is, as yet, unknown, a number of risk factors for the development of necrotizing enterocolitis have been identified. One such risk factor, formula feeding, has been shown to contribute to both increased incidence and severity of the disease. The protective influences afforded by breastfeeding are likely attributable to the unique composition of human milk, an extremely potent, biologically active fluid. This review brings together knowledge on the pathogenesis of necrotizing enterocolitis and current thinking on the instrumental role of one of the more prominent classes of bioactive components in human breast milk, glycosaminoglycans.

show abstract

“…demonstrated that curcumin prevented liver damage possibly by modulating NF‐κB translocation (Afrin et al, 2017). Therapeutic potential of curcumin in GI diseases was elaborately summarized (Burge, Gunasekaran, Eckert, & Chaaban, 2019; Kwiecien et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Combination use of tolfenamic acid with curcumin improves anti‐inflammatory activity and reduces toxicity in mice

et al. 2020

View full text Add to dashboard Cite

Long‐term use of tolfenamic acid inevitably causes side effects, including gastric ulcer and hepatotoxicity. Curcumin is generally recognized to be anti‐inflammatory, hepatoprotective, and gastroprotective. Herein, we investigated the combinational effects of tolfenamic acid and curcumin and possible mechanism in a TPA‐induced inflammation mouse model. Combinational use of tolfenamic acid (100 mg/kg) and curcumin (100 mg/kg) by oral administration reduced dermal inflammation represented by ear edema and lymphocytic infiltration. Moreover, curcumin dispersed in polyvinyl pyrrolidone showed stronger synergistic effect. The beneficial effect of the coadministration was also reproduced in PKC/Akt/IKK/NF‐κB signaling pathways. Notably, hepatoprotective and gastroprotective effect was exhibited by the reverse of body weight loss and NF‐κB downregulation in the liver, and by increased Spleen Index of mice. These results suggested combination administration of tolfenamic acid with curcumin enhances anti‐inflammatory efficacy and reduces hepatic/gastric toxicity, which indicates dietary uptake of curcumin may facilitate the function of tolfenamic acid. Practical applications Curcumin, a representative polyphenolic compound, is one of the main constituents of dietary spice turmeric which has been widely consumed throughout the world, especially in Asia. The beneficial aspect of combination use of curcumin in enhancing anti‐inflammatory effect and reducing hepatic/gastric toxicity of NSAID drug tolfenamic acid in mice has been explored. It might be anticipated as a potential naturally derived bioactive constituent in functional food and pharmaceutical applications.

show abstract

Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection

Cited by 118 publications

References 352 publications

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta‐analysis of randomized controlled trials

The Role of Glycosaminoglycans in Protection from Neonatal Necrotizing Enterocolitis: A Narrative Review

Combination use of tolfenamic acid with curcumin improves anti‐inflammatory activity and reduces toxicity in mice

Contact Info

Product

Resources

About